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Abstract: Lead optimization using drug metabolism and pharmacokinetics (DMPK) parameters has become one of the 
primary focuses of research organizations involved in drug discovery in the last decade. Using a combination of rapid in 
vivo and in vitro DMPK screening procedures on a large array of compounds during the lead optimization process has re-
sulted in development of compounds that have acceptable DMPK properties. In this review, we present a general screening 
paradigm that is currently being used as part of drug discovery at Schering-Plough and we describe a case study using the 
Hepatitis C Virus (HCV) protease inhibitor program as an example. By using the DMPK optimization tools, a potent HCV 
protease inhibitor, SCH 503034, was selected for development as a candidate drug.
Introduction
Lead optimization in a drug metabolism environment is a multifaceted operation. It typically involves the 
use of various in vitro and in vivo screens to assess the drug metabolism and pharmacokinetic (DMPK) 
properties of multiple compounds, as well as to provide an early check on the safety issues that can be 
assessed in a higher throughput manner [1–4]. This process involves interaction between DMPK scientists, 
biologists/pharmacologists and medicinal/physical chemists. The goal of the interaction is to ﬁ  nd a molecule 
that has the desired biological activity as well as DMPK properties and a safety proﬁ  le appropriate for the 
targeted therapeutic indication. In this paper, we provide an overview of the DMPK lead optimization 
process that is used to support drug discovery projects at Schering-Plough. In addition, we will demonstrate 
how the process was used in a particular program (HCV protease inhibitor) as a case study. 
Lead Generation as a Part of New Drug Discovery
Contemporary parallel and combinatorial chemical synthesis produces large arrays of compounds that are 
available for evaluation in new drug discovery. Furthermore, other improvements by structural chemists using 
a variety of tools, such as X-ray crystallography, structural modeling and ligand/substrate docking algorithms, 
and by molecular biologists developing high-throughput binding targets and cell-based activity assays provide 
drug discovery scientists with an unprecedented level of structural-based rational designs to guide the synthesis 
of new chemotypes as potential drug leads. Along with the advancement of chemistry and biology, new auto-
mated in vitro activity screening tools have become commercially available which can carry out complex, 
programmable and adaptable robotic operations to test hundred of thousands of compounds in a speedy and 
precise manner. As a result, these new forces have worked together to increase our ability to create new 
chemical entities (NCEs) that exhibit the targeted pharmacological activity.
Drug Metabolism as a Part of New Drug Discovery
Several review articles in recent years have described the role that a drug metabolism and 
pharmacokinetics (DMPK) department can play in the process of new drug discovery [1, 2, 4–11]. As 
shown in Figure 1, DMPK provides the tools and the assays to assess various new chemical entities 
(NCEs) in terms of their absorption, distribution, metabolism and excretion (ADME) properties as well 2
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as their pharmacokinetic (PK) parameters. In addi-
tion, DMPK scientists may also use various screens 
to understand the potential of NCEs for preclinical 
or clinical toxicity [12]. The goal of these efforts 
is to find a compound that is suitable for 
development. 
Lead Optimization in a DMPK 
Environment
In order to understand the needs of lead optimi-
zation, it is important to define the basic 
characteristics of drug-like leads [7]. As shown 
in Table 1, there are at least five essential 
properties that need to be considered in order for 
a compound to be drug-like: potency, bioavail-
ability, duration, safety and reasonable pharma-
ceutical properties. In addition, there are some 
other important properties, such as selectivity, 
efﬁ  cacy and dose-proportionality, to be consid-
ered. A successful clinical drug candidate must at 
least meet the minimal acceptance criteria for 
each of these ﬁ  ve properties for the type of drug 
program that is being developed. A major deﬁ  cit 
in any one of the properties may prevent the 
compound from progressing from the drug 
In-vitro ADME Screens 
+ P450 Inhibition screen 
Chemical Synthesis 
In-vivo ADME/PK Screens 
In-vivo Ancillary Pharmacology 
Screens
Candidate Selection—Compound into
Development
DMPK 
Lead 
Optimization
Figure 1. Scheme showing the iterative nature of lead optimization leading to candidate.3
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development stage to the clinical phase or to the 
market.
During the discovery phase of lead optimiza-
tion, the goal of the process is to ﬁ  nd NCEs that 
fall into the acceptable range for each of these ﬁ  ve 
properties. Among the ﬁ  ve essential properties, 
three belong to the domain of DMPK: oral 
bioavailability, duration and safety issues. Hence, 
the lead optimization in discovery DMPK could 
be divided into three categories. First, for a drug 
to be given by oral administration (as is most often 
the case), the primary goal would be improving 
the oral bioavailability. This could be achieved by 
improving either the oral absorption or reducing 
the ﬁ  rst-pass effect, or a combination of these. 
Secondly, improving the duration of the drug in 
the body could reduce the dose and the frequency 
of the dosing regimen. The duration of the drug in 
the body as measured by the half-life is inversely 
related to the systemic clearance of the compound. 
Therefore, improving (reducing) the systemic 
clearance of a series of compounds should extend 
their in vivo half-lives. Lastly, reducing any 
DMPK-related toxicity involves the use of multiple 
tests. For example, various tests are used in order 
to evaluate the potential for drug-drug interactions 
due to inhibition or induction of major CYPs, such 
as 3A4, 2D6, 1A2, 2C8, and 2C9. Another goal is 
to minimize the generation of reactive metabolites 
that may cause covalent binding. However, it is 
not totally clear whether the covalent binding may 
elicit any signiﬁ  cant toxicity.
Many well-established assays/screens are now 
available for lead optimization in the DMPK envi-
ronment (Table 2). These screens include both in 
vitro and in vivo assays. In the sections below, a 
more detailed discussion will focus on how many 
of these tools can be used in the lead optimization 
stage of new drug discovery.
Improving Oral Bioavailability 
Oral bioavailability (F) is governed by the absorp-
tion in the gastrointestinal (GI) tract and the frac-
tion of the dose that is not metabolized by the GI 
tract or the liver (the ﬁ  rst-pass effect) before it 
enters the systemic circulation. In a report by 
Chatuverdi et al. [1], oral bioavailability was 
deﬁ  ned as:
F = Fa · Fg · Fh · Fl
Fa is deﬁ  ned as the fraction of the drug that is 
absorbed across the intestinal wall, while Fg, Fh 
and Fl represent the fraction of the dosed drug that 
gets through the GI tract, the liver and the lung, 
respectively. A combination of in vitro and in vivo 
screens may be employed to assess preclinical 
absorption and used to predict human absorption. 
The in vitro approach typically relies on using 
the Caco-2 system for screening the permeability 
of the NCEs. In addition to the caco-2 system, 
other types of membrane preparations or artiﬁ  cial 
membranes, such as isolated intestinal membrane 
and PAMPA, may be also suitable for the 
screening of permeability. Numerous reports have 
documented the utility of Caco-2 screening as 
well as the correlation between the Caco-2 perme-
ability and the absorption in humans [13–16]. The 
Caco-2 system appears to be most predictable for 
compounds that are absorbed by the transcellular 
Table 1. General properties of drug-like lead compounds.
Property Deﬁ  nition/Requirement
Potency  The intrinsic ability of a compound to produce a desirable pharmacological response
  (usually measured via high throughput in vitro screens)
Oral Bioavailability  The ability of a compound to pass through multiples barriers, such as the GI tract and
  the liver in order to reach the target 
Duration (Half-life)  The ability of the compound to remain in circulation (or at the target site) for sufﬁ  cient
  time to provide a meaningful pharmacological response
Safety  The compound has sufﬁ  cient selectivity for the targeted response relative to 
  non-targeted responses so that an adequate therapeutic index exists
Pharmaceutical  The compound has suitable pharmaceutical properties, such as a reasonable
Acceptability  synthetic pathway, adequate aqueous solubility, reasonable rate of dissolution, 
   good  chemical  stability,  etc.4
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mechanism. Due to the small pore size of the tight 
junction, the Caco-2 system is less permeable to 
compounds that are absorbed by the paracellular 
mechanism. However, treatment of the Caco-2 
cells with calcium-chelating reagents, such as 
EDTA, can increase the pore size of the tight 
junctions. This approach has been used to under-
stand the potential paracellular permeability of 
lead compounds [17]. One of the drawbacks of 
using the caco-2 system is that the passive perme-
ability may be underestimated for p-glycoprotein 
(p-GP) substrates due to efﬂ  ux. The alternative 
is to use the PAMPA system which utilizes an 
artiﬁ  cial membrane, for the evaluation of passive 
permeability across membrane.
The in vivo approach to measure absorption in the 
discovery phase relies on animal pharmacokinetics. 
For instance, if the absorption of the lead compound 
is within the acceptable range in rodent and non-
rodent species, such as dogs and monkeys, it is likely 
that human absorption may be within the acceptable 
range as well. To support this hypothesis, several 
publications [18, 19] have suggested that there is a 
correlation between the animal and human absorp-
tion, despite the fact that some distinct differences, 
such as the transit time, exist in the GI physiology 
between species. 
The second element involved in the oral 
bioavailability is the ﬁ  rst-pass effect. A compound 
entering the systematic circulation from the GI 
tract needs to ﬁ  rst pass through two barriers— 
intestinal wall and the liver (this is often called the 
“ﬁ  rst-pass effect”). Both the intestinal mucosa and 
the liver are enriched in drug metabolism enzymes. 
It has been well accepted that, due to species differ-
ences, animal metabolism may not be suitable for 
predicting the ﬁ  rst-pass effect in humans. One 
common screen for estimating the human ﬁ  rst-pass 
effect is to use microsomal preparations from 
human livers. The extraction ratio calculated from 
how quickly the NCE disappears in the microsomal 
incubation, may be used to estimate the extent of 
the liver ﬁ  rst pass. With improving cryopreserva-
tion technologies, human hepatocytes have become 
a very useful tool in evaluating the metabolic clear-
ance of test articles. A major advantage of using 
hepatocytes is that they contain both phase I and 
phase II metabolic enzymes. A fairly interesting 
approach to estimate the oral bioavailability was 
recently presented by using a Caco-2/hepatocyte 
hybrid system [20]. This novel system combines 
the Caco-2 permeability assay and the liver ﬁ  rst 
pass assay into one system. As shown before [20], 
the Caco-2/hepatocyte system could provide a 
reasonable prediction of the oral bioavailability in 
humans. This approach could be used in conjunc-
tion with animal pharmacokinetic evaluation in 
lead optimization.
Optimizing the Half-life 
of a Compound Series
The half-life of a compound is determined by both 
the clearance and the volume of distribution. As the 
clearance increases, the half-life decreases. 
Conversely, for a given clearance, a higher volume 
Table 2. In vitro and In vivo DMPK screening tools. 
Assay Type  Assay  Species Relevance  References
In-vitro Caco-2  Human  [13–16]
In-vitro  Plasma Protein binding  Multiple  [39]
In-vitro Intrinsic  Clearance  Multiple  [20–23]
  (microsomes or hepatocytes)
In-vitro  CYP P450 Inhibition  Human  [25–29]
In-vitro  CYP P450 Induction  Human  [30–31]
In-vitro  CYP P450 Proﬁ  ling  Human  [40]
In-vitro Metabolite  Proﬁ  ling  Multiple 
  (microsomes or hepatocytes)
In-vitro Transporter  proﬁ  ling  Human 
In-vivo  Rapid rat PK (CARRS)  Rat 
In-vivo  Single dose PK  Rat, Dog, Monkey 
In-vivo  Single rising dose PK  Rat and Dog or Monkey 
In-vivo Metabolite  Identiﬁ  cation  Rat and Dog or Monkey 
In-vivo  Rat Mass Balance  Rat 
In-vivo  Multiple Rising Dose  Rat 5
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of distribution results in a longer half-life. For orally 
administered compounds, the apparent half-life is 
a combination of the elimination half-life and/or 
the absorption half-life. Hence, it is sometimes 
possible to develop a slow release formulation to 
extend the apparent half-life of a compound. 
However, the primary goal in the drug discovery 
phase is to optimize the half-life of the series of 
compounds. Frequently, the goal is to increase the 
half-life, while in certain cases shortening the 
half-life is the goal; half-life increase is generally 
done by trying to reduce the clearance of a 
compound. Since there are several ways to predict 
human clearance, the screening assays are designed 
according to these approaches. For example, 
allometry using animal clearance data has been 
often used to estimate the human clearance. This 
approach requires one to measure a compound’s 
clearance in at least three animal species and to use 
the animal clearances for allometric scaling. 
Therefore, using allometry to predict human clear-
ance is hardly a high-throughput process. 
In the lead optimization process, some of the most 
frequently used high-throughput in-vitro screens aim 
to predict hepatic clearance. These assays use either 
hepatic microsomes or primary hepatocytes derived 
from humans or animals. The general screening 
procedure monitors the disappearance of the NCE 
in an incubation mixture containing the compound 
and a ﬁ  xed amount of microsomes or hepatocytes 
[1, 10, 21–23]. If the disappearance of the test 
compound follows ﬁ  rst order kinetics, the rate of the 
process can be used to calculate the intrinsic clear-
ance. A number of recent publications have suggested 
that using pooled hepatocytes from human donors 
results in a reasonable correlation between the 
measured intrinsic clearance and the in vivo clear-
ance for a number of marketed compounds [24]. The 
predictive value of the hepatocyte clearance was 
demonstrated by a very good correlation (R
2  =  0.86) 
when comparing the hepatocyte intrinsic clearance 
with in vivo clearance. Hence, by reducing the 
intrinsic clearance in an in vitro hepatocyte assay 
may predict improvement of the half-life.
Safety/Toxicity Screening
Several potential safety issues can be related to 
DMPK properties. For example, toxicity due to 
drug-drug interactions that result from CYP 
isozyme inhibition or induction may cause a candi-
date drug to fail in development. In order to avoid 
these problems, NCEs are usually screened for 
their ability to inhibit major human CYP isozymes 
using either pooled human microsomes or 
supersomes which contain individual isozymes 
[17, 25–29]. It is also important to differentiate 
whether the observed inhibition is direct, metabo-
lism or mechanism-based. The difference between 
the direct and the metabolism-based inhibition is 
that the direct inhibition by the parent compound 
is reversible whereas the metabolism-based inhibi-
tion is that a metabolite is a reversible inhibitor. A 
mechanism-based inhibition occurs when a reac-
tive intermediate covalently modiﬁ  es the CYP 
enzyme. The mechanism-based inhibition is 
usually irreversible. Practically, NCEs in drug 
discovery may encounter frequent CYP inhibition 
issues due to the wide substrate speciﬁ  cities of 
major human CYP isozmes, such as 3A4, 2D6, and 
2C families. 
CYP induction may cause opposite effects of 
CYP inhibition in that the exposure of the drug 
may be reduced. In rodents, the major induction 
issue appears to be the induction of the CYP 1A, 
CYP 2B, and CYP 3A family. There are consider-
ably literatures suggesting that nuclear receptors, 
such as AhR, CAR and PXR, are involved in the 
induction of the respective CYPs [30]. In humans, 
the major induction pathway appears to be 
controlled by PXR. Administration of PXR 
agonists, such as rifampicin, causes elevated levels 
of intestinal and hepatic CYP 3A4, resulting in the 
reduction of oral bioavailability. CYP induction 
potential can be measured by certain in vitro assays, 
such as PXR-reporter gene assay and hepatocyte 
induction assay [4, 31].
Human PK Prediction
The human PK and dose regimen prediction is 
also performed in order to facilitate the design 
and implementation of a clinical program. An 
evolving paradigm of human PK prediction 
combines allometry and scaling of the in vitro 
hepatic clearance. It is generally accepted that 
allometry using animal PK data may more accu-
rately predict the volume of distribution and renal 
clearance, while it may be less accurate in 
predicting the hepatic clearance, since the meta-
bolic enzymes, especially CYP enzymes, show 
significant differences between animals and 
humans. Hence, the use of intrinsic clearance 
obtained by microsomal or hepatocyte clearance 6
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assay for the scaling of in vivo clearance serves 
as an alternative way to predict the human hepatic 
clearance. When projected clearance values from 
allometry and in vitro-in vivo scaling are in 
reasonable agreement, one can feel conﬁ  dent that 
preclinical predictions of dosing regimen will not 
be highly inaccurate.
Case study: HCV Protease 
Screening Paradigm
Hepatitis C virus
Hepatis C virus (HCV), the etiologic agent of 
non-A, non-B hepatitis, represents a world 
wide-health problem, with approximately 170 
million people infected with the virus [32]. 
Infection with HCV often leads to a chronic form 
of hepatitis. Without therapeutic intervention it 
could lead to cirrhosis, hepatic failure or hepato-
cellular carcinoma [33]. The current therapy for 
chronic HCV infection is subcutaneous injection 
of pegylated-interferon α alone or in combination 
with oral ribavirin [34]. HCV belongs to the family 
of ﬂ  aviviridae, which includes other human patho-
gens, such as Yellow Fever and West Nile Virus. 
It is an enveloped positive stranded RNA virus. 
Upon entering a suitable host cell, the HCV 
genome serves as a template for cap-independent 
translation through its 5’ internal ribosome entry 
sites. The resulting 3000 amino acid polypeptide 
undergoes both co- and post-translational proteo-
lytic maturation by host and virus-encoded prote-
ases [35]. The virus-encoded protease responsible 
for processing the non-structural (NS) portion of 
the polypeptide is located in the N-terminal region 
of the NS3 protein. The NS3 protease structure 
provided necessary details to permit rational 
structure-assisted inhibitor design. This endeavor 
targeting the enzyme-substrate binding site 
resulted in the discovery of SCH 503034, a struc-
turally novel ketoamide protease inhibitor. Recent 
proof-of-concept clinical studies with SCH 
503034 and other HCV protease inhibitors BILN-
2061 [36] and VX-950 [37] demonstrated the 
feasibility of targeting the protease.
DMPK screening paradigm
The following is a brief summary of the drug metab-
olism/pharmacokinetics process involved in the 
discovery of SCH 503034. About 10,000 compounds 
were synthesized and went through the cell-based 
assay (Replicon assay) for HCV protease inhibition 
activity. More than 1,000 compounds met the cut-off 
criterion of an IC90 of 1 µM or lower. These 
compounds were further optimized by DMPK (Fig. 2). 
Within the DMPK screening, several tiers were 
employed. In the ﬁ  rst level, several higher throughput 
screenings were deployed: cassette-accelerated rapid 
rat screen (CARRS) screening [38], human hepatocyte 
clearance, Caco-2 permeability screening, and CYP 
enzyme inhibition (including mechanism-based inhi-
bition) screening. In addition, some special screenings 
are also employed: plasma esterase/amidase screening 
and liver uptake screening. In the second level 
screening, more labor intensive assays were employed, 
such as full pharmacokinetic (PK) studies in rodent 
species and non-rodent species (monkey and dog). Of 
the 1000 compounds tested, three emerged as advance 
leads including SCH 503034. They appeared to meet 
the following acceptable DMPK criteria: moderate 
oral bioavailability in rats and dogs, absence of reac-
tive metabolite, IC50 > 5 uM for CYPs 3A4, 2D6, 
2C8, and 2C9, moderate huan hepatocyte clearance, 
and no CYP induction liability.
Following the DMPK screening process, a few 
advanced leads were identiﬁ  ed that had acceptable 
DMPK characteristics. These advanced leads went 
through a DMPK proﬁ  ling process for the ﬁ  nal 
selection of the best compound for drug develop-
ment (Level 3). These processes involved, for 
example, single rising dose studies in both rodent 
and non-rodent species to determine if desirable 
exposure multiples could be reached in the pre-
clinical toxicology program. Then, multiple dosing 
in rats was performed in order to determine whether 
the circulating compound accumulates or produces 
auto-induction. Accumulation of the compound 
may indicate that the elimination of the compound, 
whether is due to hepatic clearance or renal clear-
ance, or both, has been hampered.
Figure 3 shows the three chemotypes that were 
submitted for lead optimization in DMPK. A multi-
tude of factors were involved in selection or 
elimination of certain chemotypes. A brief 
description of the DMPK properties of each of the 
chemotypes is discussed below:
Macrocyclic compounds
An example compound from this series is SCH 
416538 (Fig. 3). This type of compound showed 
resistance to peptidases and amidases. Since a more 7
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Level 1 Screens 
Caco-2 Permeability Screen 
Human Hepatocyte Clearance Screen 
CYP Enzyme Inhibition Screen (including mechanism-based inhibition) 
hPXR Screen 
Estease/amidase stability screen 
rat liver uptake screen 
Cassette-Accelerated Rapid Rat Screen
Level 2 Screens
Rat Full PK Study 
Monkey Full PK Study 
Dog Full PK Study
Level 3 Screens 
Single Rising Dose in Rat
Single Rising Dose in 
Monkey
Rat Enzyme Induction 
Rat Metabolite ID 
Monkey Metabolite ID 
Rat Mass Balance
SCH
503034
Figure 2. DMPK screening paradigm as part of the lead optimization and candidate selection process—application to HCV compound 
selection.
rigid conformation is maintained, this chemotype 
appears to have better potency. Some compounds 
in this class had good oral bioavailability in rats. 
However, the PK in dogs and monkeys was poor 
for most of the compounds. 
Secondary amides
An example compound from this series is SCH 
446211 (Fig. 3). This chemotype showed reason-
able half-life and excellent bioavailability after 
sub-cutaneous (SC) dosing, suggesting a potential 8
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Figure 3. HCV compounds leading to SCH 503034.
dosing regimen through the SC route. Another 
advantage of this chemotype was the resistance to 
peptidases and amidases. Again, however, the oral 
bioavailability for this chemotype was very poor 
in rats and monkeys. 
Primary ketoamides
This class of compounds appeared to be very sensi-
tive to rodent amidase. They were generally more 
resistant to human and non-rodent amidases in the 
plasma. Certain compounds in this class had good 
oral bioavailability in rats and dogs, but oral 
bioavailability in monkeys was poor. The major 
advantage of this chemotype is that liver uptake 
was found to be excellent. In addition, intrinsic 
clearance in human hepatocyte was acceptable. 
One compound in this series, SCH 503034, met 
the acceptance criteria for this program and was 
advanced into development.
Series 1. Macrocycle-Example: SCH 416538 
    Pros: excellent potency, good oral PK in rats 
    Cons: poor oral PK in monkeys and dogs 
Series 2. Secondary amide-Example: SCH 446211 
    Pros: excellent sc PK in rats, good potency, resistant to amidase
    Cons: poor oral PK in rats and monkeys 
Series 3. Primary amide-Example SCH 503034 
    Pros: excellent liver uptake, good oral PK in rats and dogs 
    Cons: poor monkey PK, sensitive to rodent amidase 9
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Conclusion
Higher-throughput DMPK screens using multiple 
in vitro and in vivo techniques are now in place 
and have become an essential part of the lead 
optimization process in new drug discovery. 
Future improvements in this lead optimization 
arena may be achieved by using automated 
systems to enhance the speed of these in-vitro 
screens. There is a continuing need in the area to 
improve the ability to predict in vivo pharmaco-
kinetics by using in vitro evaluations of oral 
absorption, intestinal and hepatic ﬁ  rst pass, hepatic 
intrinsic clearance, organ uptake and efﬂ  ux medi-
ated by transporters as well as plasma and cellular 
protein binding. In the near term, we will continue 
to use the combination of in vitro systems and fast 
in vivo screening for the selection of early 
discovery leads. In addition, in vivo studies for 
evaluation of the exposure multiple and metabo-
lism and disposition may be accelerated in order 
to reduce the time to ﬁ  nal candidate selection. 
Ultimately, it may become possible to use phar-
macologically based in silico DMPK computer 
model parameters to support the rapid screening 
of drug candidates in order to shorten the time-
frame of the lead optimization process while still 
discovering candidate drugs with acceptable 
DMPK properties. 
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